

USSN 08/700,565
GRUENBERG
AMENDMENT

the cells are activated in the presence of either or both interferon- γ and IL-2 or anti-IL-4 antibody or α B7.2 mAb or TGF- β , whereby cells differentiate into Th1 cells; and

- 1
Cancel
- (c) in the absence of exogenous IL-2, inducing cell proliferation and expanding the cells under conditions that produce at least about 10^{10} cells/liter of a homogeneous population of Th1 cells, wherein: a homogeneous population of Th1 cells comprises greater than about 50% Th1 cells; and

the resulting cells do not require co-infusion of IL-2 for activity.

2
(Amended) The method of claim 22, wherein anti-IL-4 monoclonal antibodies are also present during activation.

155. (Amended) A method for generating clinically relevant numbers of Th1 cells for autologous cell therapy, comprising:

- 3
- (a) collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;
- (b) treating the cells to induce differentiation of mononuclear cells into Th1 cells, wherein the cells are treated with either or both interferon- γ and IL-2, or anti-IL-4 antibody or α B7.2 mAb or TGF- β to induce differentiation of Th1 cells; and
- (c) contacting the resulting differentiated cells with two or more different activating proteins specific for cell surface proteins present on the cells in an amount sufficient to induce *ex vivo* cell expansion, whereby clinically relevant numbers of cells for autologous cell therapy are generated, wherein the contacting is effected in the absence of exogenous IL-2.

4
(Amended) The method of claim 155, wherein the treating step occurs in the absence of exogenous cytokines.

5
(Amended) The method of claim 155, wherein the expanded cells are predominantly Th1 cells.